Company
Waylis Therap
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
12
12 still marketed
Novel approvals
10
Approvals since 2021
0
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Lunesta new use Priority reviewOct 10, 2012
- Avodart new use Jun 9, 2011
- Jalyn approved Jun 14, 2010
- Lovaza new use Sep 16, 2009
- Coreg Cr approved Dec 19, 2008
- Aciphex new use Jun 30, 2008
- Avodart new use Jun 19, 2008
- Coreg new use Priority reviewFeb 23, 2007
- Coreg Cr approved Oct 20, 2006
- Coreg new use Aug 28, 2006
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (12)
Newest FDA action first.
- Valium Diazepam · 1963
- Thioguanine Thioguanine · 1966
- Droxia Hydroxyurea · 1967
- Coreg Cr Carvedilol Phosphate · 2006
- Coreg Carvedilol · 1995
- Aciphex Rabeprazole Sodium · 1999
- Jalyn Dutasteride, Tamsulosin Hydrochloride · 2010
- Lovaza Omega-3-Acid Ethyl Esters · 2004
- Avodart Dutasteride · 2001
- Lunesta Eszopiclone · 2004
- Leukeran Chlorambucil · 1957
- Myleran Busulfan · 1954
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.